218 related articles for article (PubMed ID: 10333347)
1. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
Pool JL; Glazer R; Chiang YT; Gatlin M
J Hum Hypertens; 1999 Apr; 13(4):275-81. PubMed ID: 10333347
[TBL] [Abstract][Full Text] [Related]
2. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
[TBL] [Abstract][Full Text] [Related]
4. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker.
Pool J; Oparil S; Hedner T; Glazer R; Oddou-Stock P; Hester A
Clin Ther; 1998; 20(6):1106-14. PubMed ID: 9916605
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
6. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension.
Oparil S; Dyke S; Harris F; Kief J; James D; Hester A; Fitzsimmons S
Clin Ther; 1996; 18(5):797-810. PubMed ID: 8930424
[TBL] [Abstract][Full Text] [Related]
9. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
[TBL] [Abstract][Full Text] [Related]
10. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
11. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
Mancia G; Korlipara K; van Rossum P; Villa G; Silvert B
Blood Press Monit; 2002 Apr; 7(2):135-42. PubMed ID: 12048432
[TBL] [Abstract][Full Text] [Related]
12. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.
Benz JR; Black HR; Graff A; Reed A; Fitzsimmons S; Shi Y
J Hum Hypertens; 1998 Dec; 12(12):861-6. PubMed ID: 9883710
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
14. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
15. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
17. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.
Malacco E; Santonastaso M; Varì NA; Gargiulo A; Spagnuolo V; Bertocchi F; Palatini P;
Clin Ther; 2004 Jun; 26(6):855-65. PubMed ID: 15262456
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
Everett BM; Glynn RJ; Danielson E; Ridker PM;
Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of valsartan in patients aged > or =65 years with systolic hypertension.
Neutel JM; Bedigian MP
Clin Ther; 2000 Aug; 22(8):961-9. PubMed ID: 10972632
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
Hedner T; Oparil S; Rasmussen K; Rapelli A; Gatlin M; Kobi P; Sullivan J; Oddou-Stock P
Am J Hypertens; 1999 Apr; 12(4 Pt 1):414-7. PubMed ID: 10232502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]